Healthcare / Medical DevicesHKSE
$8.90
-0.11 (-1.22%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $5.3M · quality 43.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
62/100
B
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$2.8B
P/E
19.8x
↓EV/EBITDA
13.7x
↑ROE
8.1%
↑Gross Margin
73.9%
↑Debt/Equity
0.17
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+17.7%
FCF CAGR
—
FCF margin
10.7%
FCF / Net income
0.58x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $644.6M · net income $119.2M · FCF $69.1M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $644.6M | $644.6M | $534.0M | $473.8M | $395.5M |
| Net Income | $119.2M | $119.2M | $52.3M | $14.5M | $70.1M |
| EBITDA | $185.2M | $185.2M | $112.5M | $70.5M | $91.2M |
| EPS | 0.39 | 0.39 | 0.17 | 0.05 | 0.23 |
| Gross Margin | 73.9% | 73.9% | 75.4% | 79.6% | 85.0% |
| Operating Margin | 16.3% | 16.3% | 6.9% | 4.5% | -0.0% |
| Net Margin | 18.5% | 18.5% | 9.8% | 3.1% | 17.7% |
| Balance Sheet | |||||
| Debt/Equity | 0.17 | 0.17 | 0.15 | 0.18 | 0.04 |
| Current Ratio | 5.73 | 5.73 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $69.1M | $69.1M | $5.3M | $-92.5M | $-115.5M |
| Returns | |||||
| ROE | 8.1% | 8.1% | 3.9% | 1.1% | 5.5% |
| Valuation | |||||
| P/E | 19.78 | 19.78 | 35.88 | 214.80 | 77.39 |
| EV/EBITDA | 13.67 | 13.67 | 11.45 | 40.12 | 48.20 |
| P/B | 1.82 | 1.82 | 1.36 | 2.49 | 4.18 |
| Growth & Yield | |||||
| Revenue Growth | 20.7% | 20.7% | 12.7% | 19.8% | — |
| EPS Growth | 129.4% | 129.4% | 240.0% | -78.3% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
26.5%
EPS terminal req.
$0.79
Spread vs growth
102.9%
5Y implied EPS CAGR
19.6%
EPS terminal req.
$0.96
Spread vs growth
109.8%
10Y implied EPS CAGR
14.7%
EPS terminal req.
$1.54
Spread vs growth
114.7%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+7.6%
Start / end P/E
48.6x → 22.8x
EPS bridge
0.17 → 0.39
Residual
-68.7%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.